Pharma-Bio Serv, Inc.
Pharma-Bio Serv, Inc. (PBSV) Financial Performance & Income Statement Overview
Explore the financials of Pharma-Bio Serv, Inc. (PBSV), including yearly and quarterly data on income, cash flow, and balance sheets.
Pharma-Bio Serv, Inc. (PBSV) Income Statement & Financial Overview
View the income breakdown for Pharma-Bio Serv, Inc. PBSV across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.47M | $2.33M | $2.42M | $2.38M |
| Cost of Revenue | $1.70M | $1.61M | $1.78M | $1.76M |
| Gross Profit | $768109.00 | $726570.00 | $635384.00 | $618475.00 |
| Gross Profit Ratio | $0.31 | $0.31 | $0.26 | $0.26 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $860300.00 | $880700.00 | $1.02M | $931850.00 |
| Operating Expenses | $860300.00 | $880700.00 | $1.02M | $931850.00 |
| Total Costs & Expenses | $2.56M | $2.49M | $2.80M | $2.69M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $50825.00 | $46514.00 | $44395.00 | $44678.00 |
| EBITDA | $60474.00 | -$107616.00 | -$337387.00 | -$307867.00 |
| EBITDA Ratio | $0.02 | -$0.05 | -$0.14 | -$0.13 |
| Operating Income | -$92191.00 | -$154130.00 | -$381782.00 | -$313380.00 |
| Operating Income Ratio | -$0.04 | -$0.07 | -$0.16 | -$0.13 |
| Other Income/Expenses (Net) | $101842.00 | $139281.00 | $91592.00 | $120737.00 |
| Income Before Tax | $9651.00 | -$14849.00 | -$290190.00 | -$192638.00 |
| Income Before Tax Ratio | $0.004 | -$0.006 | -$0.12 | -$0.08 |
| Income Tax Expense | $1115.00 | -$30960.00 | $19004.00 | $21179.00 |
| Net Income | $8536.00 | $16111.00 | -$309194.00 | -$213817.00 |
| Net Income Ratio | $0.003 | $0.007 | -$0.13 | -$0.09 |
| EPS | $0.37 | $0.03 | -$0.01 | -$0.009 |
| Diluted EPS | $0.37 | $0.03 | -$0.01 | -$0.009 |
| Weighted Avg Shares Outstanding | $22.96M | $22.97M | $22.96M | $22.96M |
| Weighted Avg Shares Outstanding (Diluted) | $22.96M | $22.97M | $22.96M | $22.97M |
Over the last four quarters, Pharma-Bio Serv, Inc.'s revenue moved from $2.38M in Q2 2024 to $2.47M in Q1 2025. Operating income in Q1 2025 was -$92191.00, with a strong operating margin of -4%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Pharma-Bio Serv, Inc. remained robust at $60474.00, reflecting operational efficiency. Net income dropped to $8536.00, with an EPS of $0.37. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan